177 related articles for article (PubMed ID: 34199200)
1. Cyanovirin-N Binds Viral Envelope Proteins at the Low-Affinity Carbohydrate Binding Site without Direct Virus Neutralization Ability.
Maier I; Schiestl RH; Kontaxis G
Molecules; 2021 Jun; 26(12):. PubMed ID: 34199200
[TBL] [Abstract][Full Text] [Related]
2. Engineering recombinantly expressed lectin-based antiviral agents.
Maier I
Front Cell Infect Microbiol; 2022; 12():990875. PubMed ID: 36211961
[TBL] [Abstract][Full Text] [Related]
3. Engineering Antiviral Agents via Surface Plasmon Resonance.
Maier I
J Vis Exp; 2022 Jun; (184):. PubMed ID: 35781530
[TBL] [Abstract][Full Text] [Related]
4. Cyanovirin-N Binding to
Maier I; Kontaxis G; Zimmermann C; Steininger C
Biochemistry; 2024 May; 63(10):1270-1277. PubMed ID: 38770609
[TBL] [Abstract][Full Text] [Related]
5. Cyanovirin-N binds to the viral surface glycoprotein, GP1,2 and inhibits infectivity of Ebola virus.
Barrientos LG; O'Keefe BR; Bray M; Sanchez A; Gronenborn AM; Boyd MR
Antiviral Res; 2003 Mar; 58(1):47-56. PubMed ID: 12719006
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive functional analysis of N-linked glycans on Ebola virus GP1.
Lennemann NJ; Rhein BA; Ndungo E; Chandran K; Qiu X; Maury W
mBio; 2014 Jan; 5(1):e00862-13. PubMed ID: 24473128
[TBL] [Abstract][Full Text] [Related]
7. Hyperglycosylated stable core immunogens designed to present the CD4 binding site are preferentially recognized by broadly neutralizing antibodies.
Ingale J; Tran K; Kong L; Dey B; McKee K; Schief W; Kwong PD; Mascola JR; Wyatt RT
J Virol; 2014 Dec; 88(24):14002-16. PubMed ID: 25253346
[TBL] [Abstract][Full Text] [Related]
8. A Designed "Nested" Dimer of Cyanovirin-N Increases Antiviral Activity.
Woodrum BW; Maxwell J; Allen DM; Wilson J; Krumpe LR; Bobkov AA; Hill RB; Kibler KV; O'Keefe BR; Ghirlanda G
Viruses; 2016 Jun; 8(6):. PubMed ID: 27275831
[TBL] [Abstract][Full Text] [Related]
9. Anti-tetherin activities of HIV-1 Vpu and Ebola virus glycoprotein do not involve removal of tetherin from lipid rafts.
Lopez LA; Yang SJ; Exline CM; Rengarajan S; Haworth KG; Cannon PM
J Virol; 2012 May; 86(10):5467-80. PubMed ID: 22398279
[TBL] [Abstract][Full Text] [Related]
10. A yeast glycoprotein shows high-affinity binding to the broadly neutralizing human immunodeficiency virus antibody 2G12 and inhibits gp120 interactions with 2G12 and DC-SIGN.
Luallen RJ; Fu H; Agrawal-Gamse C; Mboudjeka I; Huang W; Lee FH; Wang LX; Doms RW; Geng Y
J Virol; 2009 May; 83(10):4861-70. PubMed ID: 19264785
[TBL] [Abstract][Full Text] [Related]
11. Targeting host O-linked glycan biosynthesis affects Ebola virus replication efficiency and reveals differential GalNAc-T acceptor site preferences on the Ebola virus glycoprotein.
Bagdonaite I; Abdurahman S; Mirandola M; Pasqual D; Frank M; Narimatsu Y; Joshi HJ; Vakhrushev SY; Salata C; Mirazimi A; Wandall HH
J Virol; 2024 Jun; 98(6):e0052424. PubMed ID: 38757972
[TBL] [Abstract][Full Text] [Related]
12. Actinohivin, a broadly neutralizing prokaryotic lectin, inhibits HIV-1 infection by specifically targeting high-mannose-type glycans on the gp120 envelope.
Hoorelbeke B; Huskens D; Férir G; François KO; Takahashi A; Van Laethem K; Schols D; Tanaka H; Balzarini J
Antimicrob Agents Chemother; 2010 Aug; 54(8):3287-301. PubMed ID: 20498311
[TBL] [Abstract][Full Text] [Related]
13. MARCH8 Inhibits Ebola Virus Glycoprotein, Human Immunodeficiency Virus Type 1 Envelope Glycoprotein, and Avian Influenza Virus H5N1 Hemagglutinin Maturation.
Yu C; Li S; Zhang X; Khan I; Ahmad I; Zhou Y; Li S; Shi J; Wang Y; Zheng YH
mBio; 2020 Sep; 11(5):. PubMed ID: 32934085
[TBL] [Abstract][Full Text] [Related]
14. Cyanovirin-N binds to gp120 to interfere with CD4-dependent human immunodeficiency virus type 1 virion binding, fusion, and infectivity but does not affect the CD4 binding site on gp120 or soluble CD4-induced conformational changes in gp120.
Esser MT; Mori T; Mondor I; Sattentau QJ; Dey B; Berger EA; Boyd MR; Lifson JD
J Virol; 1999 May; 73(5):4360-71. PubMed ID: 10196334
[TBL] [Abstract][Full Text] [Related]
15. Convergence of a common solution for broad ebolavirus neutralization by glycan cap-directed human antibodies.
Murin CD; Gilchuk P; Ilinykh PA; Huang K; Kuzmina N; Shen X; Bruhn JF; Bryan AL; Davidson E; Doranz BJ; Williamson LE; Copps J; Alkutkar T; Flyak AI; Bukreyev A; Crowe JE; Ward AB
Cell Rep; 2021 Apr; 35(2):108984. PubMed ID: 33852862
[TBL] [Abstract][Full Text] [Related]
16. Comparison of N- and O-linked glycosylation patterns of ebolavirus glycoproteins.
Collar AL; Clarke EC; Anaya E; Merrill D; Yarborough S; Anthony SM; Kuhn JH; Merle C; Theisen M; Bradfute SB
Virology; 2017 Feb; 502():39-47. PubMed ID: 27984785
[TBL] [Abstract][Full Text] [Related]
17. Host-Primed Ebola Virus GP Exposes a Hydrophobic NPC1 Receptor-Binding Pocket, Revealing a Target for Broadly Neutralizing Antibodies.
Bornholdt ZA; Ndungo E; Fusco ML; Bale S; Flyak AI; Crowe JE; Chandran K; Saphire EO
mBio; 2016 Feb; 7(1):e02154-15. PubMed ID: 26908579
[TBL] [Abstract][Full Text] [Related]
18. Antibodies elicited by yeast glycoproteins recognize HIV-1 virions and potently neutralize virions with high mannose N-glycans.
Zhang H; Fu H; Luallen RJ; Liu B; Lee FH; Doms RW; Geng Y
Vaccine; 2015 Sep; 33(39):5140-7. PubMed ID: 26277072
[TBL] [Abstract][Full Text] [Related]
19. Dissecting carbohydrate-Cyanovirin-N binding by structure-guided mutagenesis: functional implications for viral entry inhibition.
Barrientos LG; Matei E; Lasala F; Delgado R; Gronenborn AM
Protein Eng Des Sel; 2006 Dec; 19(12):525-35. PubMed ID: 17012344
[TBL] [Abstract][Full Text] [Related]
20. Comparative Analysis of the Glycosylation Profiles of Membrane-Anchored HIV-1 Envelope Glycoprotein Trimers and Soluble gp140.
Go EP; Herschhorn A; Gu C; Castillo-Menendez L; Zhang S; Mao Y; Chen H; Ding H; Wakefield JK; Hua D; Liao HX; Kappes JC; Sodroski J; Desaire H
J Virol; 2015 Aug; 89(16):8245-57. PubMed ID: 26018173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
